Keros Therapeutics (NASDAQ:KROS) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says

Keros Therapeutics (NASDAQ:KROS) had its price objective boosted by equities researchers at Wells Fargo & Company from $88.00 to $111.00 in a report issued on Wednesday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock.

KROS has been the topic of a number of other reports. HC Wainwright reiterated a “buy” rating and issued a $100.00 price objective on shares of Keros Therapeutics in a report on Thursday, November 7th. Wedbush reiterated an “outperform” rating and set a $84.00 price target on shares of Keros Therapeutics in a report on Thursday, November 7th. Guggenheim restated a “buy” rating and issued a $102.00 price objective (up from $96.00) on shares of Keros Therapeutics in a report on Wednesday, December 4th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Keros Therapeutics in a research note on Friday, November 22nd. Finally, Scotiabank initiated coverage on shares of Keros Therapeutics in a research note on Wednesday, October 16th. They issued a “sector outperform” rating and a $77.00 price target on the stock. Three research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to MarketBeat.com, Keros Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $95.22.

Keros Therapeutics Stock Performance

Shares of NASDAQ:KROS opened at $18.43 on Wednesday. Keros Therapeutics has a 52-week low of $15.67 and a 52-week high of $73.00. The business has a fifty day moving average of $59.95 and a two-hundred day moving average of $52.83.

Keros Therapeutics (NASDAQ:KROS) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The firm had revenue of $0.39 million during the quarter. During the same period in the prior year, the company earned ($1.33) earnings per share. The company’s revenue for the quarter was up 4750.0% compared to the same quarter last year. On average, analysts expect that Keros Therapeutics will post -5.26 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. KBC Group NV raised its position in Keros Therapeutics by 52.0% in the 3rd quarter. KBC Group NV now owns 1,263 shares of the company’s stock valued at $73,000 after purchasing an additional 432 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in Keros Therapeutics by 26.0% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock valued at $77,000 after acquiring an additional 280 shares in the last quarter. Values First Advisors Inc. purchased a new position in Keros Therapeutics in the third quarter worth approximately $89,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in Keros Therapeutics during the 2nd quarter worth approximately $128,000. Finally, LMR Partners LLP acquired a new position in Keros Therapeutics during the 3rd quarter worth approximately $213,000. 71.56% of the stock is currently owned by hedge funds and other institutional investors.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.